Modeling Choice Behavior for New Pharmaceutical Products  by Bingham, Matthew F. et al.
 Volume 4 • Number 1 • 2001
VALUE IN HEALTH
 
© ISPOR 1098-3015/01/$15.00/32 32–44
 
32
 
Modeling Choice Behavior for New Pharmaceutical Products
 
Matthew F. Bingham, MS,
 
1
 
 F. Reed Johnson, PhD,
 
1
 
 David Miller, PhD
 
2
A B S T R A C T
 
1
 
Triangle Economic Research, Durham, NC; 
 
2
 
Glaxo Wellcome Inc, Durham, NC
 
This paper presents a dynamic generalization of a
model often used to aid marketing decisions relating to
conventional products. The model uses stated-prefer-
ence data in a random-utility framework to predict
adoption rates for new pharmaceutical products. In ad-
dition, this paper employs a Markov model of patient
learning in drug selection. While the simple learning
rule presented here is only a rough approximation to re-
ality, this model nevertheless systematically incorpo-
rates important features including learning and the in-
fluence of shifting preferences on market share. Despite
its simplifications, the integrated framework of ran-
dom-utility and product attribute updating presented
here is capable of accommodating a variety of pharma-
ceutical marketing and development problems. This re-
search demonstrates both the strengths of stated-prefer-
ence market research and some of its shortcomings for
pharmaceutical applications.
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Introduction
 
Traditional factors influencing the acceptance of a
novel pharmaceutical compound include levels of
safety and efficacy observed in clinical trials. While
the importance of these factors remains undisputed,
cost differentials mean that clinical data may not pro-
vide sufficient information for evaluating treatment
options [1]. Decisions involving tradeoffs among ef-
ficacy, toxicity, and costs customarily are made us-
ing judgment methods derived from past successes
and failures [2]. However, natural experiments
provided by historical adoption rates of drugs with
known properties provide limited information on
likely consumer demand for novel pharmaceutical
compounds.
This paper outlines a decision model for evalu-
ating the impact of information regarding alterna-
tive treatments, toxicity, uncertainty regarding ef-
fectiveness, delivery method, and cost on demand
for unique compounds. Any approach to pharma-
coeconomic evaluation requires specification of a
viewpoint to facilitate comparison [1]. Relevant
decision-makers in this model include those groups
interested in pharmaceutical demand forecasts.
These groups could include pharmaceutical devel-
opers, marketers, and pharmacy and therapeutic
(P & T) committees faced with a difficult formu-
lary listing decision.
A number of legitimate concerns limit the use-
fulness of traditional pharmacoeconomic methods
in this arena. These concerns include potential lack
of objectivity, disregard of closely substitutable prod-
ucts, extrapolation from irrelevant populations, ig-
noring dynamic aspects of drug choice, and other
methodological issues. Shortcomings in these ar-
eas limit the usefulness of cost effectiveness (C-E)
studies for comparing competing drugs in a thera-
peutic class. This situation can lead to decision-
making based almost solely on drug cost [3]. The
increasingly competitive health care market may
put those focusing on patient satisfaction at a dis-
advantage.
Rising competition in health care has led to a
growing concern for understanding consumer pref-
erences. The increasing importance of a demand per-
spective in drug development, marketing, and for-
mulary listing decisions highlights the need for a
quantitative measure of value from the point of view
of health-care consumers. The method presented
here draws its structure from choice theory, a fun-
damental description of consumer behavior. Mod-
eling market-research data within this framework
allows estimating the parameters underlying indi-
vidual preferences. Combining these estimated pa-
rameters with price and outcome information from
related products in a random utility framework
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makes it possible to forecast initial consumer de-
mand for a new pharmaceutical compound.
Pharmaceutical consumers face uncertainty aris-
ing from imperfect information regarding product
attributes [4]. For this reason, forecasts of initial
demand may be of limited value. Specifically, as
consumers gain experience it is reasonable to ex-
pect that they will incorporate previously learned
information in current and future decisions. Of
course, consumers face uncertainty in many prod-
uct markets. However, the consequences of poor
selection in the pharmaceutical market often are
more severe and immediate than corresponding deci-
sions in conventional markets. Thus, any approach
hoping to generate future pharmaceutical demand
forecasts must consider the effect of prior experience
on subsequent choices. Here, we integrate a random-
utility decision rule with Bayesian updating in a
discrete Markov process. Because this framework
explicitly considers the influence of prior pharma-
ceutical experience on future choices it is able to gen-
erate demand forecasts for future time periods supe-
rior to forecasts arising from static models.
 
Methods
 
Multi-Attribute Utility Theory and
Health-State Preferences
 
The traditional utility maximization model provides
a framework for analyzing consumer response to
price and income changes. However, this theory is
mute with respect to preferences for nonexistent or
new goods. To explain consumer reactions to quality
changes or the introduction of new products, Lan-
caster advanced the concept now known as multi-
attribute utility theory [5]. Lancaster’s underlying te-
net is that commodities themselves do not provide
utility to the consumer. Rather, commodities typi-
cally are composed of multiple attributes contrib-
uting to satisfaction. Health outcomes arising from
pharmaceutical interventions can be thought of as
multi-attribute commodities. The attributes associ-
ated with drug use might include changes in symp-
toms experienced, mobility, and physical or social
functioning levels. The utility realized by consump-
tion of a given drug thus can be expressed as a func-
tion of the health-outcome attributes associated
with its use. Therefore, demand for a pharmaceuti-
cal compound is determined by preferences for the
health states associated with its consumption [6]. In
practice, the utility associated with a particular
treatment is often expressed as a function of drug
characteristics, patient characteristics, and health-
outcome attributes.
 
Quantifying Health-State Preferences
 
Health-care researchers have recognized the multi-
dimensional nature of health status in developing
health-status indices. Multi-attribute systems pro-
vide a concise and comprehensive framework for
describing health states. Such indices typically con-
sist of a number of health attributes. Each attribute
is composed of multiple levels. A unique combina-
tion of attributes and their associated levels com-
prises a health state. Utility weights provide the
only means of incorporating consumer preferences
in the decision model presented here. For this rea-
son, selecting the correct weights is vital. In gen-
eral, useful utility weights arise from adherence to
economic principles, careful preference elicitation,
and judicious selection of an appropriate health-
status index. The weights typically estimated from
health-status indices suffer from a variety of lim-
itations in these areas. For example, estimating
weights from the Quality of Well-Being index as-
sumes additive utility independence. This require-
ment disallows diminishing marginal utility and
interaction effects for multiple health outcomes.
These restrictions result in incorrect conclusions at
the extremes of the health attribute space [7].
The development of health-utility indices dem-
onstrates the potential for estimating utility weights
from experimental data. Unfortunately, these indi-
ces are not often flexible enough to incorporate im-
portant aspects of utility theory. Thus, the validity
of estimated utility weights using standard methods
such as QALYs is questionable. Because of these
limitations, we propose developing weights from a
stated preference (SP) survey. The weights devel-
oped from a conjoint style SP survey are capable
of representing preferences in a manner consistent
with economic theory [8]. In particular, SP tech-
niques allow both diminishing marginal utility of
health and estimation of weights for combined health
states [9]. An additional advantage of SP techniques
is the ability to include health-cost as an experimental
attribute. This feature allows conversion of marginal
utilities to marginal dollar values.
The rigorous utility-based foundations of SP
techniques and the extensive implementation of
conjoint analysis for traditional product develop-
ment suggest the promise of this technique for eval-
uating health-state preferences in a utility-theoretic
manner [10]. Like other survey methods, SP tech-
niques are not insulated from concerns about the
reliability of estimated weights. However, there is
some evidence that describing health-state attributes
in specific and familiar language leads to reliable esti-
mates. Finally, it is important that the utility weights
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capture relevant aspects of individual preferences.
The required level of responsiveness is most likely
obtained by employing a health-status index that
is sufficiently detailed and inclusive to capture rel-
evant variations in anticipated outcomes. These
complications underscore the importance of care-
ful survey development.
SP has already seen some use in valuing health
states [9,11–13]. Figure 1 illustrates a recent choice-
format SP designed to elicit respondent tradeoffs
among episode duration, symptom, daily activity lim-
itations and cost. Choice formats mimic consumer
decision-making most closely. Other formats com-
monly used for eliciting preferences include rated or
graded pairs and rankings. All formats employ an ex-
perimental design in which respondents compare a
series of attribute bundles.
Each respondent evaluates a series of such screens
that show various combinations of choices. Using a
properly specified orthogonal design, resulting data
can be analyzed to recover underlying health-state
utility parameters of interest. Combining these utility
weights with choice attributes provides estimates of
the expected utility associated with each choice.
These expected utilities provide the foundation for
predicting choice behavior under specified condi-
tions. The following sections outline the concep-
tual and empirical basis for such analysis.
 
Stated Preferences and Expected Utility
 
Careful preference elicitation and utility-weight esti-
mation facilitate accurate representation of health-
 
state preferences. For the remainder of this paper,
we will assume that these preferences are exhibited
by rational, utility-maximizing consumers. Under
these assumptions, the utility derived by using drug i
is a function of x
 
s
 
 discrete adverse health attributes,
s 
 

 
 1, . . ., S, and x
 
t
 
 discrete beneficial health at-
tributes, t 
 

 
 1, . . ., T.
(1)
where Y is disposable income and c
 
i
 
 is the pa-
tient’s cost of drug i. The marginal utility of at-
tribute s, 
 
∂
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, is negative and the marginal util-
ity of attribute t, 
 
∂
 
U
 
i
 
/
 
∂
 
x
 
t
 
, is positive. Under these
conditions, a standard multinomial logit model
employing pharmaceutical product characteristics
and outcome expectations as explanatory vari-
ables provides the basis for predicting drug choice.
In general, researchers will be interested in con-
sumer preferences about several drug attributes.
Introducing multiple attributes adds complexity to
determining utility. This complication arises be-
cause utility is a function of each attribute. In prac-
tice, determining utility can be simplified by assum-
ing some form of utility independence [7]. Utility
independence implies that preferences for a given at-
tribute are invariant with respect to levels of other
attributes. When all attributes in a multi-attribute
utility function exhibit this quality the attributes
are said to be mutually utility independent. This
simplifying assumption allows estimation of util-
ity-theoretic parameters without requiring evalua-
tion of every possible attribute combination. Un-
der the assumption of mutual utility independence
the utility of treatment alternative i can be ex-
pressed as a linear combination:
(2)
Here the 
 
x’s 
 
are measures of alternative treat-
ment attributes. The betas (
 

 
) are utility weight
parameters estimated from experimental data.
Assuming mutual utility independence greatly
simplifies utility determination without forcing
unreasonable utility restrictions. In particular, it is
important to note that this assumption does not
disallow estimating attribute interactions. In fact,
the specification considered in equation 2 could be
generalized to account for this complexity. In par-
ticular it is not required that each x represents a
single attribute. Rather, an SP experiment can be
designed such that some of the x’s represent the
interactive effects of certain health-state attributes.
The most general form is a completely expressed
multilinear utility function [14]. This specification
Ui U x( 1,…,xS,…,xS T+ ;Y ci )–=
Ui β1Xi1 β2Xi2 … βkXik+ + +=
Figure 1 Example of choice-format stated preference (SP)
design.
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requires utility weights for every possible interac-
tion. For this reason, the associated measurement
task is quite intensive. A more likely specification
might employ an experimental design specifically
developed to allow estimating interactions for pairs
of variables that researchers believe to be either
substitutes or compliments.
Utility weights measure the relative importance
of specific health attributes in determining health-
related utility. However, health outcomes arising
from pharmaceutical interventions do not occur
with certainty. Rather, outcome attributes typically
occur with some probability. The relevant proba-
bilities are those that consumers believe are associ-
ated with each attribute. In the presumed absence
of this knowledge, information arising from clinical
trials or other sources can be substituted. Individ-
ual interpretation of these probabilities is an im-
portant component of expected utility determina-
tion deserving appropriately serious consideration
in model development. Here, p
 
ij
 
 represents the proba-
bility of an attribute’s occurrence. If each attribute
occurs independently of all the other attributes, the
probability of observing some realized attribute com-
bination X
 
J
 
 is
(3)
Expected utility is the probability-weighted
sum of all possible outcome combinations X
 
J
 
.
(4)
This framework takes on behavioral content by
introducing utility maximization. We assume that
consumers choose drug i when V
 
i
 
 
 

 
 max(V
 
1
 
, . . . ,
V
 
K
 
). Here, V
 
k
 
 is the perceived expected utility of
each of K drugs in the choice set. The choice set is
limited to technically feasible alternatives, alterna-
tives that satisfy regulatory requirements, and al-
ternatives having c
 
k
 
 
 

 
 Y
 
H
 
 where Y
 
H
 
 is health-related
budget and c
 
k
 
 is the cost of each drug. The V
 
k
 
 are
summary measures that account for the desirabil-
ity of each feasible alternative relative to compet-
ing alternatives in the choice set.
 
Results
 
Simulating Choice Probabilities From a Random 
Utility Model
 
Simulating aggregate choice behavior from esti-
mated utility functions requires a rule for predict-
Pi XJ( ) pij
j J∈
∏=
Vi Pi XJ( ) U XJ( )⋅
J
∑=
 
ing behavior. One such rule widely used in market
research is that the option associated with the high-
est expected utility will be an individual’s first
choice. Simple algorithms of this sort ignore the
probabilistic nature of the choice process. Methods
that consider the error properties of choice data ad-
dress this shortcoming [15]. Thurstone’s random
utility concept allows the possibility that choice is
not determined solely on the basis of known pref-
erences and decision rules [16]. This realization is
incorporated into the present model by allowing a
residual term to represent the effect of unobserved
factors on perceived utility. These factors can in-
clude imperfect information about drug attributes
and outcome probabilities, as well as unobserved
variations in tastes and random errors among de-
cision-makers. Viewed in this manner individual
j’s perceived expected utility is the sum of system-
atic and random components.
(5)
Utility maximization subject to constraints forms
the basis for random-utility theory. However, an
observed choice does not always represent the alter-
native with the highest utility. Rather, this option
has the highest sum of systematic and random util-
ity components. The random component allows the
realistic possibility that any allowable alternative
will be chosen only with some probability. At the
same time, random utility precludes the possibility
that an option always dominates all others in the
choice set. Evaluating choice probabilities in this
framework requires quantifying expected utilities
and specifying the associated error distribution.
McFadden integrated the concepts of random util-
ity and evaluation of commodity attributes to de-
velop a multinomial logit model of discrete choice.
McFadden’s random utility specification assumes
that the residuals 
 

 
i
 
 are independently and identi-
cally distributed with the type I extreme-value dis-
tribution whose cumulative distribution function
is exp(
 

 
e
 

 
). The empirical choice probabilities
for this random-utility model (RUM) are de-
scribed by
(6)
It follows that the predicted proportion of choices
favoring drug i, or market share S
 
i
 
, is
Vi E Ui( ) εij+=
Prob i( chosen X Y c ), , e
V i
e
Vk
k 1=
K
∑
--------------=
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(7)
where n denotes individual n, n 
 

 
 1, . . ., N. Note
that the market share predictions of equation 7
depend upon the influence of individual character-
istics on drug choice. Because SP surveys allow es-
timating individual specific models this specification
is technically correct. However, if individual data is
either irrelevant or unavailable, market share pre-
diction is correctly specified by equation 6.
Originally, economists used discrete-choice mod-
els combined with multi-attribute utility theory to
explain observed market choices. Applications in-
clude transportation, communications, consumer
purchases, and environmental economics [17–20].
However, marketers soon recognized the value of
using discrete-choice modeling techniques to ana-
lyze data generated by hypothetical choice experi-
ments. In these experiments, respondents choose
among groups of attribute profiles. As in market
data, multi-attribute utility theory provides the
foundation for product profiles. However, the hy-
pothetical nature of such experiments allows eval-
uation of novel attributes and attribute levels. Ex-
periments of this sort provide a well-accepted
framework for estimating the demand effects of
product differentiation in traditional product mar-
kets [21].
Employing market data to forecast demand for
unique pharmaceutical products suffers from some
limitations similar to those occurring in traditional
product markets. Specifically, innovative and devel-
opmental drugs typically include features not avail-
able in the marketplace. Thus, market data cannot
be used to evaluate consumer preferences for these
attributes or pharmaceutical profiles including them.
When field surveys are employed to collect
data, the parameters of V
 
k
 
 are estimated from an
appropriate sample of observed choices. This paper
demonstrates the possibility of using stated-prefer-
ence data to estimate these parameters. Unlike ob-
served market choices, data elicited in a hypothe-
tical choice experiment allows the possibility of
evaluating preferences for innovations. Specifi-
cally, assuming a general, preference-based form
for health-related utility allows direct estimation
of the utility weights associated with pharmaceuti-
Si Prob i( chosen Xn,Yn,cn )
e
Vin
e
Vkn
k
∑
---------------
n 1=
N
∑
=
n 1=
N
∑=
 
cal attributes and the health outcomes anticipated
to arise from pharmaceutical consumption. Choice
probabilities can then be simulated by setting 
 

 
i
 
 
 

 
 0
in a random utility framework and manipulating
pharmaceutical attributes. Employed in this man-
ner, the model is capable of analyzing the impact of
a variety of factors including cost, outcomes, and
competition on anticipated drug adoption rates.
Like many traditional marketing studies, the
model presented here employs information arising
from a consumer-based, SP survey. This simplifi-
cation assumes that patients alone determine the
demand curve for prescription medications. Of
course, the essence of the prescription process in-
volves the doctor-patient relationship. Correctly
modeling patient–doctor interaction is a challeng-
ing and important component to determining drug
demand. It is generally assumed that doctors select
the drug they believe is best suited to their patient’s
condition. Stern and Trajtenberg and Crawford and
Shum provide insight into this relationship [22,23].
The model presented here assumes that the physi-
cian knows patient preferences and acts according
to his interests. Thus, like Crawford and Shum, we
view decision-making agents as patient-doctor units
attempting to maximize patient utility in each pe-
riod. The following section provides a numerical
simulation demonstrating the capabilities of this
model.
 
Numerical Simulation
 
Measuring SP preferences for pharmaceuticals re-
quires a systematic framework to characterize rel-
evant products with respect to a comprehensive
set of attributes and attribute levels. Demand for
pharmaceutical products arises directly from pref-
erences for product attributes and indirectly from
preferences for the health states realized by their
consumption. Thus, attributes and levels must en-
compass the variety of health outcomes and prod-
uct attributes associated with drug administration
in a particular disease state. Once attributes and
levels are determined they can be combined into
health-state bundles, which are used in an SP exer-
cise. Figure 2 illustrates attributes and levels for a
simulation assessing demand for competing mi-
graine treatments.
Stewart and colleagues have determined that
17.6% of women and 5.7% of men suffer from
migraine attacks [28]. The onset of migraine at-
tacks usually occurs between the ages of 25 and
55 [27–30]. The median attack rate among mi-
graineurs ranges from 0.4 to 1.5 attacks per month
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[27,29]. Thus, learning is an important compo-
nent of migraine drug selection. Integrating learning
through relief probability updating with random-util-
ity maximization provides a realistic approximation
to real-world decision-making. Using simulated
data provides an idea of model capabilities when
error structure and functional form are known. Suc-
cessive choice simulation demonstrates the model’s
capability of generating expected penetration rates
for a group of migraine medications after six months.
A primary difficulty associated with employing
SP data for pharmacoeconomic market simula-
tions of this sort arises from the uncertainty asso-
ciated with outcomes. This is particularly true for
untried products. For example, a migraine medi-
cation with an efficacy rate of 70% provides effec-
tive symptom relief for about 70% of patients
across patients per attack. Longitudinal analysis
within patients suggests that efficacy rates often
vary by patient. Thus, on any given migraine at-
tack, some patients will have a higher probability
of responding, some will have a lower probability,
but on average, 70% of patients will experience
some relief. Neither the physician nor the patient
knows what the probability will be for a specific
patient or for a particular attack. Thus, there is
imperfect information about product attributes. In
the absence of perfect knowledge, it is natural to
substitute clinical data for expected probabilities
of relief or adverse outcomes. This simplification
probably represents a realistic approximation for
first-time decision-making. However, it is doubt-
ful that a patient who has experience with a drug
retains clinical trial efficacy data as their subjec-
tive response probabilities. Rather, it is likely that
patients form a new expectation based on their
prior beliefs and their experience with the drug.
Despite the important influence of uncertainty and
learning on pharmaceutical demand, empirical eval-
uations of these factors are scarce due to data limi-
tations. In general, the aggregate market-share data
employed in pharmaceutical demand studies do not
provide the patient-level information required to
analyze decision-making under uncertainty [24,25].
However, in a departure from the static approach
dictated by aggregate data, Crawford and Shum
employ a patient-level panel dataset to investigate
the dynamics of uncertainty and learning in the
Italian market for prescription antiulcer drugs [23].
Results indicate that Bayesian updating provides an
effective structure for modeling patient’s incentive
to learn about the effectiveness of various drugs.
For the simulation, we employ an empirical ver-
sion of Bayes Rule that makes updated expected
relief probabilities a weighted average of informa-
tion from the two most recent periods in the fol-
lowing manner:
(8)
where RESPPROB
 
t-2
 
 is the subjective expected re-
sponse probability in period t-2 and RESP
 
t-1
 
 is the
patient’s actual experience in period t-1. This sim-
ple scheme provides an example of one way to in-
clude learning in a model of drug adoption. Here,
we consider learning as it relates to effectiveness.
Incorporating additional opportunities such as the
probability of experiencing an adverse event could
extend the model. In addition, it is important to
note that because the simple updating rule used
here does not vary by individual, simulation does
not require drawing from any particular distribu-
tion. A more detailed specification might include
the possibility of variation in updating. However,
this model intends to forecast market share. Mean
values of updated probabilities are sufficient for
this purpose. Below is an illustration of this Baye-
sian updating scheme integrated with random-util-
ity maximization.
Consider a patient without prior experience with
migraine medications. With the assistance of a phy-
sician the patient selects a migraine medication with
a particular attribute profile according to random-
utility maximization. Here, the Response Probabil-
E RESPPROBt( )=
w1 RESPt 1–( ) w2 RESPPROBt 2–( )+
Figure 2 Attribute and attribute levels shown in choice
comparisons.
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ity attribute level of the selected migraine medica-
tion is represented by the percentage of clinical
trial patients who experienced migraine relief when
employing this particular medication. Using the
medication results in the patient either experienc-
ing or not experiencing relief. Naturally, the out-
come associated with using the drug influences the
patient’s subjective expected relief probability as-
sociated with the drug. Here, we assume that the
expected relief probability is an equally weighted
average of the prior relief probability and the most
recently realized outcome. For example, consider a
drug (Drug A) with clinical efficacy of 70%. A
first-time patient evaluates the relief probability of
this drug at 70%. If the patient chooses drug A
and experiences relief in the first period, he up-
dates the relief probability of the drug to an equally
weighted average of 70% and 100%, or 85%.
Thus, success with a given medication in prior peri-
ods increases the likelihood of its selection in sub-
sequent periods. Similarly, failure results in a
downgrading of expected relief and a lower likeli-
hood of selection. This simple scheme provides an
example of one way to include learning in a model
of drug adoption. The updating rule we have cho-
sen is intended to be illustrative rather than repre-
sentative. However, the fast-acting nature of mi-
graine medication and the difficulty of predicting
relief for a given attack support the structure of
the learning process demonstrated here.
This updating process takes place each time a
patient suffers from a new attack. Thus, if a medi-
cation is effective, the patient’s subjective expected
probability of relief increases and it is more likely
that the patient will choose that medication again.
If it is ineffective, the individual downgrades ex-
pected relief probability and the corresponding ex-
pected utility. We employ here the assumption
that the individual maximizes random utility with
each new episode. Successes (failures) lead to up-
grading (downgrading) of selection probabilities.
Naturally, forecasting accuracy depends upon how
closely the rule used for prediction approximates
market behavior. Rust demonstrates that combin-
ing a known utility function with market data
provides sufficient information for estimating such
rules [26].
Our simulation looks at a cohort of patients
first suffering from migraines. The duration con-
sidered in such a model depends upon computa-
tional constraints and the information required
for a particular study. This particular simulation
takes place over six months and assumes each
group member faces an average of three decision-
making opportunities. Migraine data indicate that
sufferers are likely to face more than three migraines
over a six-month period. However, we consider the
possibility that headaches spontaneously resolve be-
fore treatment by including only three decision-
making opportunities. At each stage of this process,
decision-makers maximize random utility based
on assumed utility weights. We have shown that
these utility weights could be estimated from a suit-
ably designed and administered SP survey. For sim-
plicity, we consider only three drugs. The simulation
is complicated by the fact that drug attributes, in
particular expected relief probabilities, vary by epi-
sode and individual (or group). For this reason, we
introduce the notational convention that Aij repre-
sents the attribute profile of drug A for episode i
and individual j. Note, however, that all individu-
als are initially endowed with the same set of prior
beliefs regarding effectiveness and an identical up-
dating process. Thus, the three-episode decision-
making process for individual j (or group j) can be
graphically depicted as follows in Figure 3.
Note that the preceding illustration consists of
a finite number of states where the probability of
moving from one state to another is known. Markov
decisions processes (MDP) provide a means for mod-
eling such behavior over time. Markov models con-
sist of state variables st and control variables dt. These
variables are indexed over time t  0,1,2,3, . . .,T.
In the case considered here, data from the above
illustration takes the form {djt, sjt}. Here, djt and sjt
represent the decision and state of agent j at time t.
In the above illustration, the state and correspond-
ing decision of agent j at a given time are repre-
sented by the block-arrow combination associated
with that state. Note that both attribute perceptions
and expected utilities are path-dependent. That is,
levels of expected relief probability for Drug A de-
pend upon both the initial state (efficacy rate) and
experience (perceived effectiveness). Therefore, the
optimal decision at time t depends not only on the
current state st, but also on the history of the pro-
cess, dt  dtT(st,Ht-1) where Ht  (s0,d0, . . .,st-1, dt-1).
Despite this complexity, once an individual ar-
rives at a state, the model retains the Markovian
feature that the current optimal decision depends
on process history only through its influence on
the current state. Thus, the optimal decision de-
pends only upon the current state st: dt  dtT(st).
Our model reflects this property through the influ-
ence of history on the expected relief probability as-
sociated with each migraine medication. Expected re-
lief probability levels and associated Markov states
are determined by the history of choices, specifi-
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cally, successes and failures experienced by each mi-
graine sufferer. However, once attribute levels are
established for a given state, random-utility maximi-
zation and hence decision-making depend only on
the expected utility associated with each drug.
The preceding example demonstrates individual
decision-making in a Markov model of learning be-
havior. This process forms the basis for determin-
ing aggregate behavior required to estimate market
penetration over time. Determining aggregate be-
havior requires iteratively estimating the percent-
age choosing each drug by period. Successive iter-
ations divide the original population into percentages
anticipated in each Markov state. Period two deci-
sions produce percentage estimates for each state in
period three. Summing these percentages by drug
returns an estimate of market penetration for each
drug in the third period.
For the following example, we assume knowl-
edge of the parameters describing health-related
utility. We simulate data under the assumption of
these known parameters and Equation 7. Using
these simulated data, we recover estimated param-
eters by fitting a random-utility model. Choice
probabilities for the first stage then are simulated
by setting i  0 in the random utility framework
(see equation 7). This procedure generates the ex-
pected percentages of patients selecting each medi-
cation the first time they seek treatment. These
percentages represent expected market share in
the first time period. At this point, single-period
market forecasts of this sort are complete. How-
ever, imperfect knowledge of product attributes
and learning from experience mean that future
choices depend upon realized outcomes. Thus, choices
are likely to change over time. The expected percent-
age of patients responding (and not responding) to
treatments are used to determine outcomes. In this il-
lustration, these percentages are arbitrarily chosen. In
an actual application, it is expected that the analyst
will use the best available prediction of effectiveness.
Once outcomes have been determined, each
group updates relief expectations according to the
version of Bayes’ rule described earlier. This proce-
dure results in six groups of patients. Although
each of these six groups can evaluate the expected
relief probability differently, each group still only
considers three drugs at each choice occasion. After
having an experience with a drug in period one, mi-
graine patients reconsider their choices employing
information learned in period one to influence
choices in period two.
For the simulation, we employed a 34  22 or-
thogonal design to represent four migraine drug
attributes with three levels, these include response
time, relief probability, reoccurrence probability,
and cost. Delivery system is oral, nasal, or inject-
able. Thus, in the experimental design, delivery sys-
tem is a categorical variable represented by binary
variables for nasal and injectable delivery where oral
delivery is the omitted category. At this point, we
postulate a set of parameter values and simulate ran-
dom-utility data accordingly. Our simulated data em-
ploys 5000 responses. Thus, these simulated data
might represent the hypothetical responses of 500
survey participants answering 10 choice questions.
Each choice question consists of two drug profiles.
The expected utility of each drug profile is gener-
ated mathematically using hypothetical drug pro-
Figure 3 Three-episode decision-making process:
Decision 1. Individual j has not previously sought treatment
for migraines. Thus, individual j chooses drug B (Decision 0)
based on random-utility maximization and attributes of all
drugs. Expected response-probability attributes for all drugs
are efficacy rates arising from clinical trials.
Decision 2. Individual j treats the second migraine with Drug
A. He then updates the expected relief probability for drug A
based on experience in State 2. The individual retains the ex-
pected relief probability for drug B from State 2. The ex-
pected relief probability for drug C still arises solely from
clinical trials data. The individual then chooses drug C (Deci-
sion 2) based on random utility maximization and attribute
levels of all drugs. At this point the simulation concludes, and
individual j is assigned to Drug C.
Decision 3. Individual j treats the migraine using drug B. The
individual then updates expected relief probability for drug B
based on experience in State 1. Individual j then chooses
drug A (Decision 1) based on random utility maximization
and attribute levels of all drugs. The response-probability at-
tribute for drug B (PBj) is updated but PAj and PCj are still effi-
cacy rates. In the third period, individual j treats the third mi-
graine with Drug C.
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files, postulated parameter values, and an additive
random utility term. Our hypothetical survey sub-
jects select the profile with the highest sum of sys-
tematic and random utility components. Survey
responses and hypothetical drug profiles comprise
the data used in multinomial logit estimation. The
postulated and estimated parameter values are as
follows in Table 1.
For this example, we consider three drugs. The
patient population being evaluated has not previ-
ously suffered from migraines. Thus, they employ
only clinical-trial response data on the first choice
occasion. Entering period one, the drug profiles
are as follows in Table 2.
Simulating choice probabilities in a random-
utility framework results in division of the original
population into three groups depending upon drug
choice. Percentages choosing each drug are simply
the choice probabilities arising from the random-
utility formulation. After one period, the cohort of
migraine sufferers falls into one of six groups de-
pending upon the drug they chose and its success
in relieving the migraine. Period one probabilities
are established using random-utility maximization
in the following manner.
Period One Probabilities
Period two probabilities are established by ran-
dom-utility maximization using updated response
probabilities from period one. After two periods,
the cohort of migraine sufferers falls into one of
36 categories. The defining feature of each cate-
gory is the level of the expected response attribute
for each drug. In Markov notation, the optimal
decision at time t depends not only on the current
state st, but also on the history of the process, dt 
P A1( ) P A( chosen Xn,Yn,cn )
e
Vin
e
Vkn
k
∑
---------------
n 1=
n
∑
=
n 1=
N
∑=
P B1( ) P B( chosen Xn,Yn,cn )
e
Vin
e
Vkn
k
∑
---------------
n 1=
N
∑
=
n 1=
N
∑=
dtT(st,Ht-1) where Ht  (s0,d0, . . .,st-1,dt-1).
Despite this complexity, once an individual ar-
rives at a state, the model retains the Markovian
feature that the current optimal decision depends
on process history only through its influence on
the current state. Thus, the optimal decision de-
pends only upon the current state st: dt  dtT(st).
We employ the notation X1RY2R where X1 and Y2
represent the drugs taken in periods one and two,
respectively, and R is the negative (N) or positive
(Y) response in the associated period. Thus, B1N A2P
means that Drug B was taken in period one with a
negative response and drug A was taken in period
two with a positive response. Therefore, estimating
period three market penetration requires successive
estimation and summation over the space including
these 36 possible states for each drug. Period three
probabilities are established as follows.
Period Three Probabilities
P A3( ) P A( 3 A1YA2P ) …
P A3( A1nC2N ) …
P A( 3 B1NA2P ) …
P A3( B1NC2N ) …
P A( 3 C1PA2P ) …
P A3( C1NC2N )
+
+ +
+ +
+ +
+ +
+
=
P B3( ) P B( 3 A1PA2P ) …
P B( 3 A1NC2N ) …
P B( 3 B1NA2P ) …
P B3 B1NC2N )( …
P B( 3 C1PA2P ) …
P B( 3 C1NC2N )
+
+ +
+ +
+ +
+ +
+
=
P C3( ) P C( 3 A1PA2P ) …
P C( 3 A1NC2N ) …+
P C( 3 B1NA2P ) …
P C( 3 B1NC2N ) …
P C( 3 C1PA2P ) …
P C( 3 C1NC2N )
+
+
+ +
+ +
+ +
+
=
Table 1 Postulated and estimated parameter values
Parameters Postulated Estimated Standard Error
Response Time .04 .013 .041
Recurrence Probability .045 .042 .002
Response Probability .05 .046 .001
Cost .03 .029 .002
Delivery—nasal .01 .006 .034
Delivery—injection .08 .088 .040
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Given our assumed parameters, random-utility
maximization in period one leads to the following
market shares:
P(A1)  47.3
P(B1)  21.3
P(C1)  31.3
After adjusting for the responses in period one
migraine patients again choose a medication based
on random-utility maximization.
Probability of selecting A—period two (by re-
sponse group)
P(A2A1Y)  0.53
P(A2A1N)  0.10
P(A2B1Y)  0.42
P(A2B1N)  0.57
P(A2C1Y)  0.36
P(A2C1N)  0.63
Probability of selecting B—period two (by re-
sponse group)
P(B2A1Y)  0.20
P(B2A1N)  0.36
P(B2B1Y)  0.30
P(B2B1N)  0.04
P(B2C1Y)  0.16
P(B2C1N)  0.28
Probability of selecting C—period two (by re-
sponse group)
P(C2A1Y)  0.27
P(C2A1N)  0.53
P(C2B1Y)  0.27
P(C2B1N)  0.38
P(C2C1Y)  0.47
P(C2C1N)  0.08
Finally, using the period three probability for-
mulas established earlier, it is possible to establish
expected market penetration for drugs A, B, and C
during period three; these penetration rates are
44%, 22%, and 33%, respectively.
These choice probabilities arise from a con-
structed learning rule. However, the rule does
seem to generate somewhat realistic probabilities.
Note that the probability of choosing a given drug
in period two is always higher (lower) if the drug
was successfully (unsuccessfully) employed in pe-
riod one. Similarly, period three choice probabili-
ties depend upon both decisions and outcomes in
prior periods.
The model presented here represents decision-
making by a set of primitives (u, p, B). The utility
function u (st,dt) represents the agent’s preferences
at time t. The Markov transition probability p
(st1dt1) represents the agent’s subjective belief
about uncertain future states. These agents behave
according to an optimal decision rule dt  d(st).
Identification of (u, p, d, B) depend upon data
availability and what restrictions the analyst is will-
ing to impose.
Here, we utilize general econometric and be-
havioral restrictions to draw on a number of pow-
erful and well-accepted results from the extensive
literature on estimation of static discrete-choice mod-
els [31]. This literature indicates that Equation 7, the
mathematical representation of random utility deci-
sion-making, provides a reasonable approximation
to observed behavior. Thus, we postulate the optimal
decision rule (dt) is maximization of expected utility.
Employing multinomial logit estimation imposes this
decision rule on either experimental or market data.
This technique is readily available in most economet-
ric software. In this example, we illustrate the advan-
tages of collecting experimental data about prefer-
ences relating to a unique compound. Specifically,
data collected from a choice-based survey like the in-
strument presented earlier allows recovering individ-
ual utility functions (uj) related to pharmaceutical
compounds with unique attributes.
In this example, the subjective relief probability
(Pt ) enters utility directly. Under the assumptions
of constant utility parameters (u) and decision rule
(d), (Pt) represents the agent’s subjective belief about
uncertain future states and is the only time variant
factor influencing the Markov transition probabil-
ity. In general, estimating such subjective beliefs is a
difficult, data-intensive task [26]. However, because
optimal decision-making depends heavily on (Pt),
inaccurately estimating this value will contaminate
ultimate market share predictions. Therefore, cor-
rectly identifying the rule used for updating the suc-
cess probability associated with each drug is critical.
Table 2 Drug attribute profiles
Drug Response Time Recurrence Probability Response Probability Cost Delivery Method
A 1.5 hours 15% 90% $30 Oral
B 2 hours 30% 80% $20 Nasal
C 2 hours 15% 70% $10 Injectable
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In this work, we used a simple Bayesian updating
scheme for illustrative purposes. Knowledge of the
Bayesian updating scheme along with past decisions
and outcomes allows determination of (Pt) for each
group.
Given the importance of (Pt) in this model, it is
natural to question how one might empirically es-
timate the function that gives rise to it. If one were
to observe market behavior subsequent to estimat-
ing utility parameters from experimental data we
need only apply the restriction that the decision
rule takes the form of Equation 7. Doing so allows
mathematical derivation of the subjective relief prob-
abilities by observing market shares at each period in
the following manner.
Assume that the period two market shares above
are not forecast from a postulated updating rule.
Rather, suppose these shares are observed and the
updating rule is unknown. In this case, using the
known drug profiles and estimated utility parame-
ters presented earlier allows algebraic identifica-
tion of the updated subjective response probabil-
ity. For example, Drug A was selected by 47.3%
in the first period. If Drug A were effective in the
first period, patients update the response probabil-
ity attribute. This updating results in a 53% mar-
ket share for Drug A in period two for the group
of patients who successfully employed Drug A in
period one. Replacing the utility function for each
drug with its calculated value allows solving for
Si Prob i( chosen Xn,Yn,cn )
e
Vin
e
Vkn
k
∑
---------------
n 1=
N
∑
=
n 1=
N
∑=
P A( 2 A1Y ) .53;P B( 2 B1Y )˙
.30˙;P C( 2 C1Y ) .47
= =
=
.53 e
VAn
e
VAn e
VBn e
VCn+ +
--------------------------------------- ;
.30 e
VBn
e
VAn e
VBn e
VCn+ +
--------------------------------------- ;
.47 e
YCn
e
VAn e
VBn e
VCn+ +
---------------------------------------
=
=
=
the updated Response Probability associated with
Drug A. Because this group of patients has no per-
sonal experience with Drugs B and C, the ex-
pected utilities associated with these drugs are un-
changed.
The exponentiated utilities associated with each
drug can be expressed as follows:
And, using the following market share informa-
tion from period two, Group A1Y
it is straightforward to solve for the updated sub-
jective response probability attribute algebraically
yielding
Subjective response probabilities for groups with
different drug selection and response patterns can
be identified in a similar fashion.
Conclusion
This paper presents a dynamic variation of a model
often used to aid marketing decisions relating to
conventional products. The model uses stated-pref-
erence data in a random-utility framework to pre-
dict adoption rates for new pharmaceutical prod-
ucts. The relevance of such a model for assessing
EU Drug A( )
.130 )( 1.5( ) .042 )( 15( )
.046( ) SRPA A1Y( )
.029 )( 30( ) 1( ) 0( ) ?=+
–
+–
=
EU Drug B( )
.130( ) 2( ) . 042( ) 30( )
.046( ) 80( ) .029( ) 20( )
1( ) .006( ) 2.094=
––
+–
=
EU Drug C( )
.130( ) 2( ) .042( ) 15( )
.046( ) 70( ) .029( ) 10( )
1( ) .088( ) 2.472=
––
+–
=
eVA A1Y e
1.305 .046( ) SRPA( A1Y )+=
eVB A1Y e
2.094 8.117= =
eVc A1Y e
2.472 11.846= =
.53 e
VAn
e
VAn e
VBn e
VCn+ +
--------------------------------------- ;=
SRPA A1Y( ) 95=
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real-world decisions depends critically on the em-
pirical validity of the assumed random-utility func-
tions. More realistic specifications require informa-
tion on what drugs are included in the actual choice
set, knowledge of perceptions regarding adverse
and beneficial outcomes with their associated prob-
abilities, and marginal rates of substitution among
drug attributes and cost. Reliable preference infor-
mation can arise from a suitable design, adminis-
tration, and analysis of an SP survey [8]. This model
focuses on patient preferences derived from an SP
survey. However, even with an informed consumer,
physicians still must act as agents for patients. If the
consumer and physician assign different expected
utilities to various drugs, the analyst is confronted
with a principal-agent problem. This complexity
can occur even if principals believe they are acting
in the best interests of agents. The present work
takes a first step toward examining demand. How-
ever, the dependence of the consumption decision
on both patient and physician is not recognized in
the model. Explicitly incorporating this important
aspect of demand determination is a relevant ave-
nue for future research.
In addition, this paper presents a Markov model
of patient learning in drug selection. The simple
learning rule presented here likely presents a rough
approximation to reality. More closely approxi-
mating weighting rules used in real-world decision-
making will improve demand forecasts. Better
estimates of such rules can arise from analyzing
additional SP survey data, market data, or a com-
bination of these sources [32]. This model empha-
sizes the importance of learning and the influence of
shifting preferences on market share. Thus, this re-
search demonstrates both the strengths of stated-
preference market research and its shortcomings for
pharmaceutical applications. The integrated frame-
work of random-utility and product attribute up-
dating presented here is capable of accommodating
a variety of pharmaceutical marketing and develop-
ment problems. We have presented a model of
how rational agents should behave under specified
learning and decision rules. However, extending
this framework could prove useful for the empiri-
cal evaluation of actual consumer behavior. Specif-
ically, modeling stated-preference data gives insight
into the form and parameters of the utility function
underlying individual choice. Combined with mar-
ket data, this information provides sufficient restric-
tions to allow model identification and estimation
of the learning rule that governs attribute percep-
tions [26]. Thus, the union of experimental and
market data holds strong promise for the variety
of difficult pharmaceutical marketing problems
that are complicated by learning, uncertainty, and
choice.
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ADDENDUM
Please note the following correction: The abstract PGU15, on page 361 of Value in Health 3(5),
entitled Costs and resources associated with the treatment of overactive bladder using retrospec-
tive medical care claims data, Williamson T, Hall J, Nelson M, Meyer J, should include the name
Wagner S in the author listing.
